TY - JOUR
T1 - Refractory Hypothyroidism
T2 - Unraveling the Complexities of Diagnosis and Management
AU - Quiroz-Aldave, Juan Eduardo
AU - Concepción-Zavaleta, Marcio José
AU - Durand-Vásquez, María del Carmen
AU - Concepción-Urteaga, Luis Alberto
AU - Gamarra-Osorio, Elman Rolando
AU - Suárez-Rojas, Jacsel
AU - Rafael-Robles, Luciana del Pilar
AU - Paz-Ibarra, José
AU - Román-González, Alejandro
N1 - Publisher Copyright:
© 2023 AACE
PY - 2023/12
Y1 - 2023/12
N2 - Introduction: Refractory hypothyroidism (RH) represents a challenge in the diagnosis and treatment within the field of thyroidology. It is defined as the inability to achieve disease control despite using levothyroxine (LT4) doses of 1.9 μg/kg/d or higher. Methods: A comprehensive review, encompassing 103 articles, was conducted using the Scielo, Scopus, and EMBASE databases, providing an approach to evaluation and diagnosis of this condition. Results: LT4 disintegrates and dissolves within an acidic gastric environment before being absorbed in the jejunum and ileum. It then extensively binds to serum transporter proteins and undergoes deiodination to yield tri-iodothyronine, the biologically active hormone. There are various nonpathological causes of RH, such as noncompliance with treatment, changes in the brand of LT4, food and drug interferences, as well as pregnancy. Pathological causes include lactose intolerance, Helicobacter pylori infection, giardiasis, among others. The diagnosis of RH involves conducting a thorough medical history and requesting relevant laboratory tests to rule out causes of treatment resistance. The LT4 absorption test allows for the identification of cases of malabsorption. The treatment of RH involves identifying and addressing the underlying causes of noncompliance or malabsorption. In cases of pseudomalabsorption, supervised and weekly administration of LT4 may be considered. Discussion: Early recognition of RH and correction of its underlying cause are of utmost importance, as this avoids the use of excessive doses of LT4 and prevents cardiovascular and bone complications associated with this condition.
AB - Introduction: Refractory hypothyroidism (RH) represents a challenge in the diagnosis and treatment within the field of thyroidology. It is defined as the inability to achieve disease control despite using levothyroxine (LT4) doses of 1.9 μg/kg/d or higher. Methods: A comprehensive review, encompassing 103 articles, was conducted using the Scielo, Scopus, and EMBASE databases, providing an approach to evaluation and diagnosis of this condition. Results: LT4 disintegrates and dissolves within an acidic gastric environment before being absorbed in the jejunum and ileum. It then extensively binds to serum transporter proteins and undergoes deiodination to yield tri-iodothyronine, the biologically active hormone. There are various nonpathological causes of RH, such as noncompliance with treatment, changes in the brand of LT4, food and drug interferences, as well as pregnancy. Pathological causes include lactose intolerance, Helicobacter pylori infection, giardiasis, among others. The diagnosis of RH involves conducting a thorough medical history and requesting relevant laboratory tests to rule out causes of treatment resistance. The LT4 absorption test allows for the identification of cases of malabsorption. The treatment of RH involves identifying and addressing the underlying causes of noncompliance or malabsorption. In cases of pseudomalabsorption, supervised and weekly administration of LT4 may be considered. Discussion: Early recognition of RH and correction of its underlying cause are of utmost importance, as this avoids the use of excessive doses of LT4 and prevents cardiovascular and bone complications associated with this condition.
KW - Malabsorption Syndromes
KW - Patient Compliance
KW - Therapeutics
KW - Thyroxine
KW - hypothyroidism
UR - http://www.scopus.com/inward/record.url?scp=85173146842&partnerID=8YFLogxK
U2 - 10.1016/j.eprac.2023.09.003
DO - 10.1016/j.eprac.2023.09.003
M3 - Artículo de revisión
C2 - 37714332
AN - SCOPUS:85173146842
SN - 1530-891X
VL - 29
SP - 1007
EP - 1016
JO - Endocrine Practice
JF - Endocrine Practice
IS - 12
ER -